The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SAN JUAN, Puerto Rico, July 08, 2026--(BUSINESS WIRE)--CorePlus, Puerto Rico's fully digital precision pathology and clinical laboratory, announced today the integration of the ArteraAI Prostate Test ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence, Swedish ...

・Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

Artera, the Los Altos, California-based developer of tools to diagnose cancer, has launched the first artificial intelligence (AI) test to guide patients in making informed decisions between active ...

The ArteraAI Prostate Test is now available to predict mortality risk and guide treatment for metastatic hormone-sensitive prostate cancer. The ArteraAI Prostate Test was launched to provide a digital ...

Please provide your email address to receive an email when new articles are posted on . MyProstateScore 2.0 showed high sensitivity for detecting aggressive prostate cancer without the need for a ...

Add Yahoo as a preferred source to see more of our stories on Google. b' Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023 ...

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...

CorePlus Integrates AI-Powered Prostate Cancer Risk Stratification Tool into its Digital Pathology Diagnostic Pathway — a First in Puerto Rico CorePlus, Puerto Rico’s fully digital precision pathology ...

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...